Cambridge Antibody Technology v Abbott Biotechnology Ltd & Anor [2004] EWHC 2974 (Pat) (20 December 2004)

Cambridge Antibody Technology v Abbott Biotechnology Ltd & Anor [2004] EWHC 2974 (Pat) (20 December 2004)

The royalty offset provision in the agreements is construed to permit Abbott to offset 50% of royalties paid to third parties for patented technology used in the development and manufacture of HUMIRA, including post-CAT technology, subject to a 2% minimum royalty to CAT. The language and factual matrix support Abbott's construction. CAT's claims for rectification and estoppel fail as the evidence does not establish a common or unilateral mistake or conduct giving rise to estoppel.

Citation
[2004] EWHC 2974 (Pat)
Parties
Claimant: Cambridge Antibody Technology Ltd; Defendant: Abbott Biotechnology Limited; Defendant: Abbott GmbH & Co KG
Jurisdiction
England and Wales
Judgment Date
20 December 2004
Procedural Posture
Commercial Contract Dispute (patent Licensing) / High Court Trial Judgment
Outcome
Claim dismissed
Legal Topics
Patent Licensing, Contract Interpretation, Rectification, Estoppel, Royalty Provisions
Intellectual Property Contract Law Patent Licensing Contract Interpretation Rectification Estoppel Royalty Provisions

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 3 Authorities cited 5 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Parties

Cambridge Antibody Technology Ltd

Claimant

Abbott Biotechnology Limited

Defendant

Abbott GmbH & Co KG

Defendant

Procedural Posture

Commercial Contract Dispute (patent Licensing) / High Court Trial Judgment

Legal Issues

  1. 1 Proper construction of royalty offset provisions in patent licence agreements
  2. 2 Whether offset applies to royalties paid for third party patents covering post-CAT technology
  3. 3 Rectification for mistake (common or unilateral)

Ratio Decidendi

The royalty offset provision in the agreements is construed to permit Abbott to offset 50% of royalties paid to third parties for patented technology used in the development and manufacture of HUMIRA, including post-CAT technology, subject to a 2% minimum royalty to CAT. The language and factual matrix support Abbott's construction. CAT's claims for rectification and estoppel fail as the evidence does not establish a common or unilateral mistake or conduct giving rise to estoppel.

Court Disposition

Claim dismissed

Orders

  • CAT's claim for additional royalties is dismissed
  • CAT's claims for rectification and estoppel are dismissed